Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ ultrasound system

 Philips receives FDA 510(k) clearance for its innovative ultra mobile VISIQ
                              ultrasound system

Transducer-plus-tablet display delivers excellent image quality, making
ultrasound available anytime, in a wide range of clinical environments for OB

PR Newswire

ANDOVER, Mass., July 24, 2014

ANDOVER, Mass., July 24, 2014 /PRNewswire/ --Royal Philips (NYSE: PHG AEX:
PHIA) today announced that it has received 510(k) clearance from the U.S. Food
and Drug Administration to market its innovative ultra mobile ultrasound
system, VISIQ, in the U.S. VISIQ is the first Philips ultrasound system to
combine the benefits of greater mobility, performance and simplicity into a
single miniaturized solution, helping clinicians increase access to quality
diagnostic scans for more OB patients.

Object: application/x-shockwave-flash

This breakthrough ultrasound device can be easily transported wherever care is
needed, and its quick-start technology and long battery life make it an ideal
system for physician offices, hospitals and other clinical settings.

"VISIQ marks a new vision in ultrasound for Philips by allowing physicians to
perform on-the-spot diagnostic scans, limiting the need for patients to go to
multiple locations or schedule return visits," said Gene Saragnese, CEO,
Imaging Systems, Philips Healthcare. "VISIQ is the latest example of Philips'
continued commitment to create advanced innovative technology solutions to
deliver better care at lower cost and to help improve patient outcomes."

VISIQ's touch-screen gesture controls are familiar to anyone who has used a
smartphone or tablet. It allows users to easily capture images, take
measurements and share data. In addition, VISIQ offers many of the automatic
image optimization features found on Philips' premium EPIQ system, as well as
built-in Wi-Fi for DICOM data transfer to hospital or cloud-based PACS.

At the heart of the VISIQ system is a smart transducer that fits comfortably
into the user's hand. Drawing on more than 30 years of experience in
ultrasound, Philips has taken advantage of advances in miniaturization to
integrate a sophisticated broadband micro-digital beam former and powerful
image acquisition module into the transducer. VISIQ targets OB and abdominal
applications and lays the foundation for a future range of portable ultrasound
products to meet the evolving needs of clinicians and patients.

"Portable and convenient, VISIQ is so intuitive, with remarkable, easy-to-use
measurement capabilities for maternal-fetal medicine specialists or general
obstetricians," said Dr. Michael Ruma, maternal-fetal medicine specialist at
Perinatal Associates of New Mexico. "Instead of just listening to the baby's
heartbeat, clinicians are able to see the baby in 2D and color."

VISIQ is also commercially available in China, East Africa, France, Germany
and India.

For more information on VISIQ and the full suite of Philips innovative
ultrasound solutions, visit:

Leslie Lakis
Philips Healthcare Communications, Imaging Systems
Tel: +1 (978) 659-3748

About Royal Philips:
Royal Philips (NYSE: PHG, AEX: PHIA) is a diversified health and well-being
company, focused on improving people's lives through meaningful innovation in
the areas of Healthcare, Consumer Lifestyle and Lighting. Headquartered in the
Netherlands, Philips posted 2013 sales of EUR 23.3 billion and employs
approximately 113,000 employees with sales and services in more than 100
countries. The company is a leader in cardiac care, acute care and home
healthcare, energy efficient lighting solutions and new lighting applications,
as well as male shaving and grooming and oral healthcare. News from Philips is
located at

Forward-looking statements:
This release may containcertain forward-looking statements with respect to
the financial condition, results of operations and business of Philips and
certain of the plans and objectives of Philips with respect to these items.By
their nature, forward-looking statements involve risk and uncertainty because
they relate to events and depend on circumstances that will occur in the
future and there are many factors that could cause actual results and
developments to differ materially from those expressed or implied by these
forward-looking statements.

Perform on-the-spot diagnostic scans with Philips' VISIQ ultrasound system

VISIQ combines the benefits of mobility, performance and simplicity into a
miniaturized solution.

Royal Philips.

Video -
Photo -
Photo -
Logo -

SOURCE Royal Philips
Press spacebar to pause and continue. Press esc to stop.